Jatenzo in Adolescents (Ages 12 to 17): Developmental Impact, Risks, and Clinical Guidance

What Is Jatenzo and Why Does Its Use in Adolescents Matter?

Jatenzo is the first oral testosterone replacement approved by the FDA, cleared in March 2019 for adult males whose hypogonadism stems from a medical condition such as Klinefelter syndrome, structural hypothalamic or pituitary disease, or orchiectomy. Its active ingredient, testosterone undecanoate, is absorbed via the intestinal lymphatic system, bypassing first-pass hepatic metabolism. That mechanism is what separates it from older oral androgens and reduces, but does not eliminate, hepatotoxicity risk.

The adolescent age band of 12 to 17 sits in a distinct biological window. Testosterone drives the entire cascade of male puberty: spermatogenesis, penile and testicular growth, voice deepening, skeletal muscle accumulation, and the epiphyseal growth-plate changes that determine adult height. Introducing exogenous testosterone through a pharmacologic agent during this window amplifies every one of those processes simultaneously, with the possibility of compressing a sequence that normally unfolds over 4 to 6 years into a much shorter interval.

Jatenzo is not labeled for this population. Any prescribing clinician who considers it for a 12-to-17-year-old is working off-label and bears the burden of documenting the clinical rationale, the absence of better-studied alternatives, and a rigorous monitoring plan. The FDA prescribing information for Jatenzo states explicitly: "Safety and efficacy in pediatric patients below the age of 18 years have not been established." [1]

How Jatenzo Is Absorbed Differently From Injectable Testosterone

Standard testosterone cypionate or enanthate injections produce a supraphysiologic spike in the first 24 to 48 hours, then decline toward the lower end of normal before the next injection. Jatenzo, taken twice daily with food, produces a more stable serum testosterone profile across the day, though concentrations still vary with meal fat content. A higher-fat meal increases lymphatic absorption. In the key Phase 3 study (N=166 adult hypogonadal males, 16-week open-label), 87% of participants achieved average testosterone concentrations in the normal adult male range of 300 to 1,000 ng/dL. [2]

That pharmacokinetic profile has not been studied in males aged 12 to 17, where hepatic enzyme maturation, body composition, gastrointestinal transit time, and lymphatic capacity all differ from adults.

Why Adolescents With Hypogonadism Still Need Treatment

Leaving a 14-year-old with confirmed primary hypogonadism untreated is not a neutral choice. Testosterone deficiency during puberty produces delayed secondary sexual characteristics, reduced bone mineral density, psychological distress, and long-term fertility impairment. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend initiating testosterone therapy in hypogonadal males who have symptoms or signs of testosterone deficiency." [3] The question is not whether to treat, but which agent, at which dose, with which monitoring protocol.

Bone Age Acceleration: The Primary Developmental Risk

Testosterone is aromatized to estradiol in peripheral tissues, and it is estradiol, not testosterone itself, that drives epiphyseal fusion in both males and females. This distinction matters clinically. Any testosterone preparation that raises serum testosterone will also raise serum estradiol via aromatase activity in bone and adipose tissue. Higher estradiol concentrations signal the growth plates to close.

In a healthy male adolescent, growth plates remain open (Risser grade 0 to 2) through mid-puberty and fuse progressively between ages 14 and 18 depending on genetic and nutritional factors. Exogenous androgen therapy can advance skeletal maturation by 1 to 2 bone-age years beyond chronologic age within 12 months of treatment, as documented in studies of testosterone therapy for constitutional delay of growth and puberty (CDGP). [4]

How Bone Age Is Measured and When to Order It

Bone age is determined from a plain radiograph of the left hand and wrist, interpreted against the Greulich and Pyle atlas or the Tanner-Whitehouse method. The test is low-cost, low-radiation, and reproducible. Any clinician initiating androgen therapy in a male aged 12 to 17 should:

1. Obtain a baseline bone age radiograph before the first dose.
2. Repeat the radiograph every 6 months during active treatment.
3. Stop or reduce androgen therapy if bone age advances more than 1 year beyond chronologic age in a single 6-month interval.

No published Jatenzo-specific data exist for this monitoring protocol in adolescents. The above interval derives from protocols used for injectable testosterone in CDGP studies and from Endocrine Society pediatric endocrinology consensus. [3, 4]

Projected Height Loss From Premature Epiphyseal Closure

Growth plate closure cuts off potential adult height. The degree of height loss is proportional to how open the plates were at the time of closure and how many centimeters of predicted growth remained. A boy at bone age 13 with a predicted adult height of 178 cm who undergoes premature epiphyseal closure equivalent to bone age 16 may lose 4 to 7 cm of final adult stature, based on the Bayley-Pinneau prediction tables. [5] This is not a reversible loss.

Pubertal Staging and Hormonal Trajectory

Tanner Staging During Androgen Therapy

Tanner staging (SMR 1 to 5) documents the physical progression of puberty across genital development and pubic hair in males. In a hypogonadal adolescent, the goal of testosterone therapy is to mirror the pace of natural puberty, moving the patient from Tanner I or II toward Tanner V over approximately 3 to 4 years. Compressing that timeline by using adult replacement doses from the outset risks:

• Rapid testicular atrophy secondary to gonadotropin suppression (LH and FSH suppression by negative feedback)
• Accelerated sexual development that may cause psychological distress
• Irreversible effects on spermatogenesis if treatment begins before the testis has initiated its own steroidogenesis

Jatenzo's labeled starting dose for adults is 237 mg twice daily, titrated up to 396 mg twice daily or down to 158 mg twice daily based on serum testosterone at trough. Those doses target adult normal ranges. A 12-year-old at Tanner I with no endogenous testosterone production would require a substantially lower starting dose to approximate the gradual testosterone rise of early natural puberty (roughly 20 to 50 ng/dL in early puberty, rising to 300 to 600 ng/dL in late puberty over 3 to 4 years). No FDA-approved or pediatric-guideline-validated dosing schema exists for Jatenzo in this age range.

LH and FSH Suppression

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis via negative feedback on GnRH pulsatility. In adolescent males with secondary hypogonadism (pituitary disease, Kallmann syndrome), suppressing what residual LH secretion exists may compromise any testicular function that remains. In primary hypogonadism (Klinefelter syndrome, anorchia), this suppression is less consequential because testicular function is already lost or severely impaired. The distinction between primary and secondary hypogonadism is therefore essential before initiating any androgen therapy in an adolescent. [6]

Cardiovascular and Blood Pressure Risks Specific to Adolescents

The FDA added a boxed warning to Jatenzo's label in 2019 for blood pressure elevation. In the key Phase 3 trial, mean systolic blood pressure increased by 3.5 mmHg and diastolic blood pressure by 2.0 mmHg from baseline over 16 weeks of treatment in adult males. [2] About 5% of trial participants required new or intensified antihypertensive medication.

Adolescents are not immune to hypertension. The American Heart Association defines hypertension in adolescents aged 13 and older as sustained blood pressure at or above the 95th percentile for age, sex, and height on repeated measurements, or above 130/80 mmHg. [7] An adolescent with underlying kidney disease, obesity, or a family history of cardiovascular disease who is started on Jatenzo faces an additive hypertensive burden.

Polycythemia in Growing Males

Testosterone stimulates erythropoietin production, raising red cell mass and hematocrit. The labeled contraindication in adults is a hematocrit above 54%. In adolescents, the reference ranges for hematocrit shift with age and puberty: a 12-year-old's normal hematocrit (37 to 44%) differs from a 17-year-old's (39 to 50%). Clinicians monitoring a 14-year-old on Jatenzo should apply age-specific pediatric reference ranges, not adult thresholds, and obtain a complete blood count at baseline and every 3 to 6 months during treatment. [8]

Sleep Apnea Worsening

Testosterone therapy worsens obstructive sleep apnea in susceptible individuals, a risk noted in the FDA label. Adolescents with obesity, Down syndrome, or craniofacial abnormalities already carry elevated sleep apnea prevalence. Screening for symptoms (witnessed apneas, daytime somnolence, morning headaches) is indicated before and during therapy.

Comparing Jatenzo to Standard-of-Care Options for Adolescent Hypogonadism

The table below organizes the currently available testosterone formulations by their relative evidence base and practical characteristics in the adolescent setting. Injectable testosterone esters remain the most guideline-referenced option for pediatric hypogonadism because dose titration is straightforward, monitoring protocols are well-established, and decades of real-world use exist in this population.

| Formulation | Route | Dosing flexibility for pubertal induction | Pediatric guideline support | Key adolescent-specific concern | |---|---|---|---|---| | Testosterone enanthate | IM injection | High (25 to 100 mg every 2 to 4 weeks, titrated up) | Endocrine Society 2018 [3] | Injection pain; supraphysiologic peaks | | Testosterone cypionate | IM injection | High (similar to enanthate) | Widely used in pediatric practice | Same as enanthate | | Testosterone gel (1%) | Transdermal | Moderate | Limited pediatric data | Transfer risk to others; variable absorption | | Testosterone undecanoate (Jatenzo, oral) | Oral | Low (capsule sizes limit fine titration) | No pediatric guideline endorsement | Meal-fat dependence; BP elevation; no pediatric PK data | | Testosterone pellets | Subcutaneous implant | Very low (fixed dose per pellet) | Minimal pediatric data | Irreversibility of each insertion; infection risk |

The Endocrine Society 2018 guideline specifically states: "We recommend against the routine use of oral androgens in male hypogonadism because of their limited efficacy, potential for hepatotoxicity (17-alkylated androgens), and adverse lipid profiles." [3] Testosterone undecanoate (Jatenzo) is not a 17-alkylated androgen and avoids the hepatotoxicity of methyltestosterone, but the guideline's preference for injectable preparations in the context of pubertal induction remains the clinical standard.

Laboratory Monitoring Protocol for Any Adolescent on Androgen Therapy

Close monitoring is not optional when treating a developing patient with exogenous androgens. The following schedule derives from Endocrine Society pediatric endocrinology recommendations and standard pediatric practice. Note that these parameters are not Jatenzo-specific because Jatenzo has no published pediatric protocol. Clinicians extrapolate from injectable testosterone monitoring standards. [3, 6]

At Baseline (Before First Dose)

• Serum total testosterone (morning, fasting)
• LH and FSH (to confirm primary vs. Secondary hypogonadism)
• Estradiol (baseline, to assess aromatization)
• Complete blood count with hematocrit
• Comprehensive metabolic panel (hepatic and renal function)
• Fasting lipid panel
• Blood pressure (triplicate measurements)
• Bone age radiograph (left hand and wrist)
• Tanner staging (documented in chart)
• Height and weight (to calculate projected adult height)
• Testicular volume by orchidometer (Prader)

Every 3 Months During the First Year

• Serum total and free testosterone (trough for Jatenzo, taken before the morning dose)
• Blood pressure
• Symptom review (acne severity, mood changes, sleep quality, erections)
• Height and weight

Every 6 Months

• Bone age radiograph
• Tanner staging
• Complete blood count with hematocrit
• Fasting lipid panel
• Testicular volume

Annually

• Dual-energy X-ray absorptiometry (DXA) for bone mineral density if the patient has been hypogonadal for more than 12 months before treatment initiation. Prolonged hypogonadism before puberty suppresses bone accrual and creates fracture risk independent of the treatment agent. [9]

Psychological and Behavioral Developmental Considerations

Testosterone has direct effects on the adolescent brain, a structure that is itself undergoing significant pruning and myelination through age 25. Animal and human data show that androgen receptors are expressed throughout the limbic system, prefrontal cortex, and amygdala. Testosterone exposure during adolescence shapes aggression regulation, risk-taking behavior, and emotional reactivity.

A 2018 meta-analysis published in Neuroscience and Biobehavioral Reviews (34 studies, N=9,219 participants) found that higher endogenous testosterone correlated with increased reward sensitivity and reduced impulse control in males aged 10 to 18. [10] Supraphysiologic testosterone exposure from exogenous administration could amplify these effects. Clinicians prescribing androgen therapy to an adolescent should document a behavioral baseline and maintain periodic behavioral screening throughout treatment.

Acne vulgaris, which is androgen-driven, can worsen significantly during testosterone therapy. Severe nodulo-cystic acne at Tanner IV, V is associated with poorer self-esteem and social withdrawal in adolescents. Proactive dermatologic co-management (topical retinoids, benzoyl peroxide, and in severe cases oral isotretinoin) may reduce this burden.

Practical Prescribing Considerations: When Jatenzo May Be Considered Off-Label in a 12-to-17-Year-Old

Jatenzo might be considered in an adolescent only when all of the following conditions are met:

1. Primary or secondary hypogonadism is confirmed by two morning testosterone measurements below the age-appropriate lower limit, combined with appropriate LH and FSH values.
2. All standard-of-care alternatives (injectable testosterone esters) have been tried and are contraindicated or refused by the patient after full counseling.
3. The patient can reliably take capsules with a fatty meal twice daily (Jatenzo requires 20 to 30% of meal calories from fat for adequate absorption).
4. A pediatric endocrinologist or adolescent medicine specialist with experience in hypogonadism management is co-managing the case.
5. The family and patient have received and documented informed consent covering the absence of pediatric safety data, bone age risk, blood pressure risk, and pubertal timing effects.
6. A bone age radiograph has been obtained at baseline and a follow-up radiograph is scheduled at the 6-month mark.

Even meeting all six criteria, injectable testosterone at low induction doses (testosterone enanthate 25 to 50 mg IM every 4 weeks, titrated upward by 25 to 50 mg increments every 6 months) remains the approach with the broadest evidence base for pubertal induction in adolescent males. [3, 6]

Klinefelter Syndrome: The Most Common Clinical Context

Klinefelter syndrome (47,XXY) affects approximately 1 in 660 males and is the most common chromosomal cause of primary hypogonadism. Many patients are diagnosed during adolescence when expected pubertal progression fails to occur or proceeds only partially. Testosterone therapy in Klinefelter syndrome during adolescence is well-supported: it improves virilization, bone density, cognition, and quality of life. [11]

Because Klinefelter syndrome represents primary testicular failure, LH and FSH are elevated, and there is no risk of further suppressing a functional HPG axis. This makes it a setting where testosterone therapy is unambiguous. Jatenzo has not been studied in adolescents with Klinefelter syndrome, but the clinical rationale for treatment is strong. Injectable testosterone enanthate or cypionate at pubertal induction doses remains the first choice. If a transition to oral therapy is desired for quality-of-life reasons in a 16-to-17-year-old who is approaching full bone maturity (Risser grade 3 to 4), Jatenzo could be considered as a bridge formulation, with the caveat that off-label status persists and blood pressure monitoring continues.

The Journal of Clinical Endocrinology and Metabolism published a 2020 systematic review concluding that testosterone therapy in Klinefelter syndrome "significantly improves bone mineral density, lean mass, and quality of life but requires individualized dosing to avoid premature epiphyseal fusion." [11]

Fertility and Long-Term Reproductive Considerations

Testosterone therapy suppresses spermatogenesis by reducing intratesticular testosterone concentrations, which requires concentrations 50 to 100 times higher than serum levels. In adolescent males with secondary hypogonadism, initiating exogenous testosterone before the testis has been stimulated with gonadotropin therapy (hCG with or without FSH) may impair the development of Sertoli cell populations that are established during puberty and are critical for adult spermatogenesis.

A 2014 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that in males with hypogonadotropic hypogonadism, earlier gonadotropin therapy correlated with larger testicular volume and higher sperm counts at adulthood compared with those who received testosterone alone. [12] This finding supports a gonadotropin-first or gonadotropin-combined approach in adolescent males with secondary hypogonadism who wish to preserve fertility potential.

Jatenzo, like all exogenous testosterone preparations, will suppress LH and FSH and therefore will not support spermatogenesis. Adolescent patients and their families should be explicitly counseled about this trade-off before initiation.